BOSTON SCIENTIFIC CORP (BSX) 45.81 -0.1 (-0.22%)
45.81 -0.1 (-0.22%)
US1011371077 - Common Stock - After market: 46.1 +0.29 (+0.63%)
Fundamental Rating
Taking everything into account, BSX scores 3 out of 10 in our fundamental rating. BSX was compared to 222 industry peers in the Health Care Equipment & Supplies industry. The financial health of BSX is medium. Also its profitability is quite bad. While showing a medium growth rate, BSX is valued expensive at the moment.
Profitability
Profitability Rating
BSX has a Piotroski-F score of 6.00. This indicates an average health and profitability for BSX.
BSX has a Return On Assets of 1.87%. This is below the industry average of 6.83%. 93% of the industry peers outperform BSX.
BSX's Return On Equity of 3.38% is worse than the rest of the industry. The industry average Return On Equity is 10.59%. 89% of the industry peers have a better Return On Equity.
BSX has a Profit Margin of 4.75%. This is below the industry average of 12.35%. 85% of the industry peers outperform BSX.
VS Industry
ROA (1.87%) VS Industry: 7% outperformed.
0.53
117.69
ROE (3.38%) VS Industry: 11% outperformed.
0.69
140.68
Profit Margin (4.75%) VS Industry: 15% outperformed.
1.07
1,450.19
Valuation
Valuation Rating
BSX's Price/Earning Ratio is in line with the industry average which is at 26.79.
The Forward Price/Earnings Ratio of 23.38 indicates a rather expensive current valuation of BSX.
With a price book ratio of 3.72, BSX is valued correctly.
When comparing the price book ratio of BSX to the average industry price book ratio of 2.75, BSX is valued in line with its industry peers.
The Price/Earnings Ratio is 26.79, which means the current valuation is very expensive for BSX.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
When comparing the Enterprise Value to EBITDA ratio of BSX to the average industry ratio of 20.65, BSX is valued more expensive than its industry peers.
VS Industry
Price/Earnings (26.79) VS Industry: 49% outperformed.
2,272.73
2.16
Price/Book (3.72) VS Industry: 42% outperformed.
1,294.43
0.17
Enterprise Value/ EBITDA (23.7) VS Industry: 36% outperformed.
6,048.87
0.01
Growth
Growth Rating
The Earnings Per Share has grown by an impressive 21.28% over the past year.
BSX is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 10.11% yearly.
The EPS growth is accelerating: in the next 5 years the growth will be better than in the last years.
Measured over the past 5 years, BSX shows a small growth in Earnings Per Share. The EPS has been growing by 7.79% on average per year.
BSX shows a small growth in Revenue. In the last year, the Revenue has grown by 9.56%.
Measured over the past 5 years, BSX shows a small growth in Revenue. The Revenue has been growing by 7.23% on average per year.
BSX is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 7.00% yearly.
The Revenue growth is stable: in the next 5 years the growth will be about the same than in the last 5 years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 7.79% | 3.27% | 21.28% | 7.39% | 9.63% | 10.55% | 10.11% |
| Revenue | 7.23% | 6.57% | 9.56% | 6.93% | 6.44% | 6.78% | 7% |
Health
Health Rating
BSX has an Altman-Z score of 3.38. This indicates that BSX is financially healthy and little risk of bankruptcy at the moment.
BSX is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of 1.87.
A Current Ratio of 1.45 indicates that BSX should not have too much problems paying its short term obligations.
The Piotroski-F score of BSX is 6.00. This is a neutral score and indicates average health and profitability for BSX.
Compared to an average industry Current Ratio of 3.75, BSX is worse placed to pay its short term obligations than its industry peers. 86% of its industry peers have a better Current Ratio.
A Quick Ratio of 0.95 indicates that BSX may have some problems paying its short term obligations.
Compared to an average industry Quick Ratio of 2.92, BSX is worse placed to pay its short term obligations than its industry peers. 89% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.11, BSX is more dependent on financing than its industry peers.
VS Industry
Debt/Equity (0.49) VS Industry: 25% outperformed.
336.87
0.00
Quick Ratio (0.95) VS Industry: 11% outperformed.
0.06
33.20
Current Ratio (1.45) VS Industry: 14% outperformed.
0.12
33.20
Altman-Z (3.38) VS Industry: 65% outperformed.
-101.82
77.09
Dividend
Dividend Rating
No dividends for BSX!.
BOSTON SCIENTIFIC CORP45.81
NYSE:BSX (1/30/2023, 7:04:01 PM)-0.1 (-0.22%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Health Care Equipment & Services | ||
| GICS Industry | Health Care Equipment & Supplies | ||
| Earnings (Last) | 10-26 2022-10-26/bmo | Earnings (Next) | 01-31 2023-01-31 |
| Inst Owners | 91.58% | Inst Owner Change | -0.08% |
| Ins Owners | 0.23% | Ins Owner Change | -1.13% |
| Market Cap | 65.61B | Analysts | 83.53 |
| Price Target | 52.37 (14.32%) | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | 9.21% | Ex-Date | N/A |
| EPS beat(2) | 1 | Avg EPS beat(2) | -0.42% |
| Min EPS beat(2) | -3.49% | Max EPS beat(2) | 2.65% |
| EPS beat(4) | 3 | Avg EPS beat(4) | 0.2% |
| Min EPS beat(4) | -3.49% | Max EPS beat(4) | 2.65% |
| Revenue beat(2) | 1 | Avg Revenue beat(2) | -0.01% |
| Min Revenue beat(2) | -0.15% | Max Revenue beat(2) | 0.13% |
| Revenue beat(4) | 2 | Avg Revenue beat(4) | 0.22% |
| Min Revenue beat(4) | -0.48% | Max Revenue beat(4) | 1.37% |
| PT rev (1m) | 2.46% | EPS NQ rev (1m) | 0% |
| EPS NY rev (1m) | 0% | Revenue NQ rev (1m) | 0% |
| Revenue NY rev (1m) | 0% | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.79 | ||
| Fwd PE | 23.38 | ||
| P/S | 5.22 | ||
| P/FCF | 108.27 | ||
| P/OCF | 54.82 | ||
| P/B | 3.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.7 |
| EPS(TTM) | 1.71 | EY | 3.73% |
| EPS(NY) | 1.96 | Fwd EY | 4.28% |
| FCF(TTM) | 0.42 | FCFY | 0.92% |
| OCF(TTM) | 0.84 | OCFY | 1.82% |
| SpS | 8.77 | BVpS | 12.32 |
| TBVpS | -0.89 | PEG (NY) | 3.63 |
| PEG (5Y) | 3.44 | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.87% | ||
| ROE | 3.38% | ||
| ROIC | 5.54% | ||
| ROICexc | 5.6% | ||
| ROICexgc | 17.18% | ||
| OM | 15.84% | ||
| PM | 4.75% | ||
| GM | 68.89% |
| ROICexgc(3y) | 15.99% | ROICexcg growth 3Y | -41.44% |
| ROICexcg growth 5Y | -19% | ROICexc(3y) | 4.96% |
| ROICexc growth 3Y | -10.06% | ROICexc growth 5Y | -2.82% |
| OM growth 3Y | 0.12% | OM growth 5Y | 2.14% |
| PM growth 3Y | -21.32% | PM growth 5Y | 14.9% |
| GM growth 3Y | -0.99% | GM growth 5Y | -0.44% |
| F-Score | 6 | Asset Turnover | 0.39 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 14.17 | ||
| Debt/EBITDA | 2.75 | ||
| Cap/Depr | 52.21% | ||
| Profit Quality | 101.51% | ||
| Current Ratio | 1.45 | ||
| Quick Ratio | 0.95 | ||
| Altman-Z | 3.38 |
| F-Score | 6 | WACC | 8.67% |
| ROIC/WACC | 1.98 | Cap/Depr(3y) | 52.5% |
| Cap/Depr(5y) | 53.08% | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | 21.28% | EPS 3Y | 3.27% |
| EPS 5Y | 7.79% | EPS growth Q2Q | 4.88% |
| EPS Next Y | 7.39% | EPS Next 2Y | 9.63% |
| EPS Next 3Y | 10.55% | EPS Next 5Y | 10.11% |
| Revenue growth 1Y | 9.56% | Revenue growth 3Y | 6.57% |
| Revenue growth 5Y | 7.23% | Revenue growth Q2Q | 8.12% |
| Revenue Next Year | 6.93% | Revenue Next 2Y | 6.44% |
| Revenue Next 3Y | 6.78% | Revenue Next 5Y | 7% |
| EBIT growth 1Y | 20.75% | EBIT growth 3Y | 6.69% |
| EBIT growth 5Y | 9.53% | EBIT Next Year | 21.4% |
| EBIT Next 3Y | 12.57% | EBIT Next 5Y | 8.72% |
| FCF growth 1Y | -38.29% | FCF growth 3Y | N/A |
| FCF growth 5Y | 14.34% | OCF growth 1Y | -21.61% |
| OCF growth 3Y | 82.27% | OCF growth 5Y | 9.62% |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA